INmune Bio Inc (INMB)

Form 8-K - Current report

INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion

Secures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Program...

INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™

Approval of pediatric strategy validates clinical data package and accelerates the regulatory path for...

Form 8-K - Current report

INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB

MHRA minutes from May 12 pre-MAA Scientific Advice meeting confirm agreement across all questions covering CMC...

Form 8-K - Current report

Form 8-K - Current report

INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial

XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200...

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes Canada NewsWire SAN FRANCISCO, May...

INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform

Boca Raton, FL, May 15, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a clinical-stage...

Form 8-K - Current report

INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease

BOCA RATON, FL, May 14, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB), a late-stage biotechnology...

INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point

Alliance launches with 26 founding companies to develop a national strategy for U.S. biotechnology leadership...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]